Document is current

Article History

Received: 30 January 2023

Revised: 20 September 2023

Accepted: 2 October 2023

First Online: 24 October 2023

Competing interests

: SVP has received honoraria or research funds from Aifred; Assurex; Janssen; Mensante; Sage Therapeutics, Inc.; and Takeda. STA has received research support from COMPASS Pathways and Neuronetics; has served as a consultant to Genomind, Inc.; Janssen; LivaNova PLC; Neuronetics; and Sage Therapeutics, Inc.; and has served on speaker boards for Janssen and Sunovion Pharmaceuticals, Inc. SJM has served as a consultant to Allergan; Alkermes; Almatica Pharma; Axsome Therapeutics; BioXcel Therapeutics; Boehringer-Ingelheim; Clexio Biosciences; COMPASS Pathways; Eleusis; EMA Wellness; Engrail Therapeutics; Greenwich Biosciences; Intra-Cellular Therapies; Janssen; Levo Therapeutics; Perception Neurosciences; Praxis Precision Medicines; Neumora; Neurocrine; Relmada Therapeutics; Sage Therapeutics, Inc.; Seelos Therapeutics; Signant Health; and Sunovion and has received research support from Biohaven Pharmaceuticals; Boehringer-Ingelheim; Janssen; Merck; Sage Therapeutics, Inc.; and VistaGen Therapeutics. GA has received research support from Accera, Allergan, Axovant, Eisai, Genentech, Intra-Cellular Therapies, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Suven, and TransTech, and has served on the speakers bureau or as a consultant for Acadia, Alkermes, Allergan, Avanir, Janssen, Lundbeck, Merck, Nestle, Otsuka, Sunovion, Takeda, and Vanda. CD has received grant support from Biolite, Janssen, Neuronetics, and St. Jude, and has served on the advisory board of Alkermes. SK was an employee of Sage Therapeutics, Inc., at the time this trial was conducted and may hold stock in Sage Therapeutics, Inc., but is currently an employee of EmbarkNeuro. RL, AB, JJu, JJo, TV, and JD are employees of Sage Therapeutics, Inc., and may hold stock and/or stock options. MK, FF, and BL are employees of Biogen, Inc., and may hold stock.